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Introduction
During clinical research, investigators may discover 
infor ma tion with important health implications for a 
participant but that is not relevant to the initial aims of 
the study. Investigators and ethicists have been grappling 
with the question of how to address such incidental 
research fi ndings for years. Th e ethical and practical 
considerations underlying this question are complex and 
often involve issues such as the researcher­participant 
relationship, the ethical practice of research, the cost and 
burden of follow­up, and participant expectations, 
among many other factors. Th e question of how to 
address incidental research fi ndings becomes even more 
complicated in the context of clinical trials, in which 
participants may expect investigators to keep their 
medical best interests in mind, or researchers may feel 
obligated to report potentially important health fi ndings 
to their participants. Clinical trials that involve genomic 
analyses add another level of complexity to the reporting 
of incidental fi ndings because genomic studies can 
generate data on hundreds of thousands of genetic 
fi ndings, most with unknown or evolving clinical signi fi ­
cance. As the fi eld of genomics continues to develop, 
there will be an increased need for shared experience and 
guidance on how to handle the discovery of incidental 
genetic research fi ndings.
Th is paper discusses the process of developing the 
GARNET recommendations on incidental genetic fi nd ings 
in the context of clinical trials, and explores the ethical 
and practical issues considered in formulating our 
recommendations.
GARNET
GARNET comprises a series of genome­wide association 
studies (GWAS) of treatment responses in randomized 
clinical trials that aim to identify the genetic variants 
associated with response to treatments for conditions of 
clinical or public health signifi cance [1]. Th e clinical trials 
that make up GARNET are the Women’s Health Initiative 
(WHI) Hormone Th erapy Trial, designed to identify 
genetic variations that alter the risk of coronary heart 
disease, stroke, venous thromboembolism and incident 
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diabetes after exposure to hormone therapy; the 
SUCCESS A breast cancer trial, which aims to identify 
genetic variations that influence the efficacy or toxicity of 
chemotherapy for breast cancer; and the Vitamin Inter­
vention for Stroke Prevention (VISP) trial, designed to 
identify genetic variants that influence the risk of recur­
rent stroke, myocardial infarction or death in response to 
vitamin therapy. GARNET utilizes existing clinical trial 
data and sample resources to identify genetic variants 
that influence an individual’s response to treatment, to 
determine whether specific treatments are more or less 
effective in groups defined by genotype, and to develop 
and disseminate innovative methods for adding genome­
wide technologies to randomized clinical trials and 
interpreting the results in the context of a randomized 
treatment assignment. For a variety of historical reasons, 
consent forms for the clinical trials included in GARNET 
explicitly state that results will not be returned to parti ci­
pants. However, owing to investigator concerns about the 
possibility of encountering a potentially actionable 
genetic result, GARNET created an Incidental Findings 
Sub committee to consider how to handle any such 
results.
After finding limited information on how to handle 
incidental genetic findings and individual research results 
when adding genome­wide analyses to clinical trials, the 
GARNET Incidental Findings Subcommittee set out to 
develop an approach as part of the goal of developing and 
disseminating methods for adding genome­wide tech no­
lo gies to randomized clinical trials (Box  1). The recom­
mendations below are taken from [1,2].
The GARNET recommendations were made after a 
review of the studies’ consent forms and the existing 
litera ture regarding the return of individual research 
results and incidental findings in clinical trial and genetic 
research settings. From the outset, it was thought 
important to determine the kinds of incidental findings 
found when performing genome­wide genotyping, in 
order to provide information about this for researchers 
working on studies in which genomic analyses are 
prospectively or retrospectively incorporated into clinical 
trials. The precedent for this was set by the GENEVA con­
sortium [3], which encourages research groups perform­
ing genome­wide association studies, such as GARNET, 
to think prospectively about how clinically relevant inci­
dental findings will be addressed within their studies [4].
The Subcommittee also felt that IRBs and other study­
specific governing bodies should be actively involved 
when making decisions on when and how to report 
incidental genetic findings to individuals, since responsi­
bility for overseeing study policies and procedures, 
investi gator conduct, and participant safety is a shared 
responsibility. The Subcommittee felt that any return of 
results should be done in collaboration with a genetic 
medicine clinic because these clinics use Clinical Labora­
tory Improvement Amendments (CLIA)­certified labora­
tories, have experience with reporting genetic results to 
individuals, and have genetic counseling and referral 
resources at their disposal.
Of the total of 10,316 research samples that were 
genotyped in the three GARNET trials, incidental genetic 
findings were found in about 1% of samples after 
performing routine data cleaning and analysis. These 
included 132 large (>10 megabase pair (Mb)) autosomal 
chromosome anomalies in 109 samples, 1  male with 
Kleinfelter’s syndrome (XXY), 7 females who had XXX or 
XXX/XX, and 16 females who were XX/XO. Some of the 
chromosomal anomalies detected in GARNET are 
similar to those found in the GENEVA GWAS con­
sortium, where they were found to have an association 
with hematological cancers [5]. However, no GARNET 
findings were raised to an actionable level, given that 
reporting the large autosome anomalies detected has no 
clear clinical utility. The sex chromosome anomaly find­
ings have possible treatment implications but were not 
raised to an actionable level as the anomalies may be 
acquired and, moreover, all participants with these 
anomalies were over reproductive age.
Discussion
In formulating our recommendations, the Subcommittee 
reviewed the ethical and practical considerations in 
support of reporting incidental genetic findings to clinical 
trial participants as well as the challenges inherent in 
doing so. Although no GARNET findings were raised to 
an actionable level, the issues we considered in making 
our recommendations apply to others facing similar 
deliberations.
Considerations in support of reporting incidental genetic 
findings to clinical trial participants
Although incidental findings in genetic studies have his­
torically had a negative connotation due to misattributed 
parentage [6], recent studies show that incidental findings 
involving health­related information are not uniformly 
regarded as unwelcome by participants, particularly if the 
information can be used to prevent or treat a disease or 
disorder [7,8]. Indeed, two National Heart, Lung, and 
Blood Institute working groups recommend that 
individual genetic results should be offered to study 
participants if: (1)  the genetic finding has important 
health implications for the participant, and the associated 
risks are established and substantial; (2)  the finding is 
actionable; (3)  the test is analytically valid; and (4)  the 
study participant has opted to receive his or her genetic 
results [9,10].
Ethical arguments supporting the disclosure of genetic 
research findings include: (1) the participant’s interest in 
Bookman et al. Genome Medicine 2013, 5:7 
http://genomemedicine.com/content/5/1/7
Page 2 of 6
information about themselves; (2) the benefit of receiving 
genetic findings, either because they can improve health 
or treatment, or because they can carry personal mean­
ing; (3)  an increase in trust in researchers from dis­
closure, ultimately leading to greater participation; (4) the 
principle of reciprocity ­ participants voluntarily agree to 
contribute to research, and should receive access to the 
knowledge gained from the research; and (5)  returning 
results is a sign of respect that represents a core ethical 
commitment in research [11].
Beskow and Burke argue that different types of studies 
result in varying levels of obligation to return genetic 
results to participants [12]. For example, family­based 
studies or research in collaboration with rare disease 
organizations confer a stronger obligation for return of 
results, whereas secondary analysis of research data or 
biobanking studies may represent a weaker obligation 
[12]. Genetic research conducted in the context of 
clinical trials differs from many other genetic studies, and 
some of these contextual differences suggest a potentially 
stronger obligation for return of results.
The Department of Health and Human Services’ 
Institutional Review Board Guidebook defines a clinical 
trial as ‘a controlled study involving human subjects, 
designed to evaluate prospectively the safety and efficacy 
of new drugs or devices or of behavioral interventions’ 
[13]. Participants often receive information about their 
clinical response, resulting in expectations that differ 
from observational studies. Thousands of people each 
year participate in clinical trials in the hope of furthering 
medical knowledge and obtaining needed medical care 
[14,15]. ‘Therapeutic misconception’, a widespread pheno­
menon, occurs when a research participant does not 
appreciate the distinction between the imperatives of 
clinical research and of medical treatment, and therefore 
inaccurately attributes therapeutic intent to research 
[16]. Because clinical trials are often performed at 
medical centers and by researchers who are also health­
care providers, participants may believe that they will 
receive healthcare benefits from their participation, 
regard less of the trial aims. Although the main goal of 
clinical research is to improve medical knowledge, many 
Box 1. GARNET recommendations for incidental findings and potentially clinically relevant genetic results when 
adding genomics to clinical trials
•	 Investigators	are	strongly	encouraged	to	catalogue	all	identified	incidental	findings	and/or	potentially	clinically	relevant	genetic	
abnormalities, results of discussions with IRBs, and actions taken, if any, so that all individuals involved in the study will have a sense of 
the scope of these issues.
•	 After	identifying	a	potentially	actionable	incidental	finding,	investigators	should	discuss	with	their	supervising	IRBs	how	to	handle	the	
genetic research results in light of the study-specific consent forms.
•	 Future	users	of	clinical	trial	data	who	identify	findings	that	they	consider	to	have	clinical	relevance	should	inform	the	primary	study	
investigator of these findings, but must understand that all decisions related to notifying research participants of incidental or research 




genetic results will be returned to participants, at a minimum the investigator should explain the study rules and try to determine the 
nature	of	the	participant’s	interest.	If	appropriate,	the	investigators	should	refer	individuals	to	a	local	genetic	medicine	clinic	that	offers	
genetic evaluation, diagnosis, assessment, genetic testing and interpretation, counseling and management, as well as referrals to 
appropriate resources for individuals with genetic disorders.
•	 Any	return	of	genetic	results	to	study	participants	should	be	done	with	the	assistance	of	and	in	collaboration	with	a	genetic	medicine	
clinic that offers genetic evaluation, diagnosis, assessment, genetic testing and interpretation, counseling and management, as well as 
referrals to appropriate resources for individuals with genetic disorders.
•	 When	preparing	for	further	contact	with	participants	in	a	research	cohort	(for	example,	informing	participants	of	important	findings	
that might affect their continued participation in a research study, as part of a re-consent process for the next phase of a longitudinal 
study, or even during a regularly scheduled periodic newsletter), as when designing new clinical trials with associated genetic studies, 
investigators are strongly encouraged to:
1. Discuss with their IRB how to present the possibility that there may be clinically relevant incidental and research findings, and 
outline	circumstances	and	procedures	for	return	of	these	results	that	respect	the	individual	participant’s	preferences,	local	IRB	
requirements,	and	national	recommendations;
2. Acknowledge in the consent forms and associated educational materials that this is an area of rapid change, and leave open the 
possibility	that	unforeseen	circumstances	may	necessitate	further	discussion	between	investigators	and	participants;	and
3. State in consent forms and associated educational materials that study participants may not be informed of important genetic 
results if investigators and their IRBs decide that no individual genetic results will be returned to participants.
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clinical trial participants believe the investigators will still 
provide the best standard of care [6]. A participant may 
also believe, when signing on to a clinical trial, that the 
investigators assume responsibility for their health, 
including that they will supply all relevant health 
information [17].
In clinical care, healthcare providers may find un­
expected abnormalities that are unrelated to a patient’s 
complaints but are essential to the patient’s health [17]. 
The healthcare provider has a responsibility to disclose 
these findings to the patient, even though that was not 
the primary reason for the examination. Many feel that 
responsibility spills over to healthcare providers when 
they are in an investigator capacity [17]. Thus, some 
argue that researchers have an obligation to respond to 
incidental findings that arise during clinical research 
owing to the nature of the professional relationship they 
have with their participants and the general duty of 
beneficence [17]. When clinical trial designs are adapted 
based on results from interim analyses, such as in adap­
tive treatment­switching designs [9,18,19], participants 
are given a greater chance of deriving medical benefit 
from their study participation and thus may also have 
increased expectations regarding disclosure of clinically 
relevant incidental finings, including incidental genetic 
findings when genetic analyses are included in the study.
Furthermore, some argue that the obligation to report 
individual results to participants increases when there is 
frequent interaction among researchers and participants, 
as in many clinical trials, because a more intense 
relationship creates a stronger ethical requirement for 
reciprocity [20]. Additionally, some believe that any 
increase in participants’ vulnerability, uncompensated 
risks or burdens, and dependence on the researcher may 
increase the researcher’s responsibility to provide ancil­
lary care to participants [21]. As such, in clinical trials in 
which the researcher­participant relationship may be 
intense and the participant may be particularly vulner­
able, the ethical duty to the participant, which may 
involve the return of incidental findings, is amplified.
Challenges in reporting incidental genetic findings to 
clinical trial participants
As in imaging studies, in which there may be incidental 
findings for a significant percentage of participants [22], 
participants in studies that involve genome­wide analyses 
may possess a vast number of variants that differ from 
reference sequences. Over 1,000 variants have been asso­
ciated with a disease or trait and more than 650 variants 
have been associated with a drug response [23,24]. In 
contrast, hundreds of thousands of variants have no 
known trait or disease association. As more knowledge is 
obtained over time, the number of associations will 
increase, as each personal genome has more than 
3  million single nucleotide polymorphisms and over 
1,000 large (>500 base pairs (bp)) copy number variants 
[25]. If clinical trials include whole exomes or whole­
genome sequencing, the number of potential incidental 
genetic findings increases exponentially. When deciding 
which, if any, incidental genetic findings should be 
reported to individual study participants, it is important 
to consider the accuracy of the test results and the 
usefulness of the information to participants. These 
criteria are generally described in terms of analytic 
validity, clinical utility and clinical validity [9,26].
Since the primary aim of research is to yield generali­
zable knowledge, some investigators feel that planning to 
disclose individual results such as incidental genetic 
findings further confuses the line between clinical care 
and research, and contributes to therapeutic misconcep­
tion [27]. An appropriate disclosure policy requires that 
participants are educated beforehand about the range of 
possible findings and that consent forms truly inform the 
research participant of the risks and benefits of the 
proposed research, and explains all possible conse­
quences from participating in the clinical trial. However, 
it is not feasible to define all the possible findings result­
ing from genomic analyses, as the number of possible 
incidental genetic findings is nearly infinite. It would also 
be impossible to describe the potential consequences of 
genomic analyses, because the implications of the 
majority of genetic variants found to date are not known. 
Finally, most genetic findings are probabilistic or pleio­
tropic, making them more complex for investigators to 
explain and for participants to comprehend [27].
Additionally, in genetic testing, there are often psycho­
logical effects on those receiving results. Participants 
receiving a positive test result may experience serious 
psychological burdens, while those receiving negative 
test results may experience a false sense of security and 
think that they will not develop the disease, not under­
standing that there is still a risk for disease roughly equal 
to the population risk [7]. Furthermore, even though the 
Genetic Information Nondiscrimination Act of 2008 
(GINA) [28] is meant to decrease the possibility of dis­
crimi nation in access to employment and health insur­
ance associated with genetic findings, there remains a 
perceived threat of social stigmatization and discrimi­
nation in access to employment, health, disability and/or 
life insurance that has important implications for disclos­
ing incidental genetic findings. These concerns also extend 
to family members of people receiving results [29].
Many investigators have stated that the practical diffi­
culty of returning incidental findings is a major barrier to 
reporting back incidental findings to partici pants. The 
large amount of information garnered from incorporating 
genome­wide technology into clinical trials causes 
practical challenges for quality assurance, data handling 
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and storage. For instance, the age and type of the 
specimen may affect test results, and cell lines made from 
primary tissue may exhibit chromosomal changes and 
mosaicism as an artifact of the transformation process. 
Sample handling and genotyping in most clinical trials is 
for research purposes only and is not performed under 
CLIA certification [30]. Current guidelines and regu la­
tions would require that investigators plan to have 
research results confirmed in a CLIA­certified laboratory 
to be appropriate for reporting to participants.
Finally, returning incidental genetic findings to indi­
viduals requires the investigator(s) who may be com muni­
cating the results to have appropriate genetic training 
and expertise [31,32]. Genetic risk for complex diseases 
can be particularly complicated and difficult to convey, 
leading to the common practice of deciding upfront not 
to return incidental genetic findings to participants and 
stating as much in the consent forms [9,33]. In a study 
looking at researcher perspectives on disclosure of 
incidental findings in genetic research, the surveyed in­
vesti gators were concerned about the considerable time, 
energy and personnel necessary for re­contacting and re­
consenting participants [34]. Disclosure of incidental 
findings can be resource intensive, and some argue that it 
would be unethical to use those resources for feedback 
when they could be used for research [35].
Conclusion
Although reporting incidental findings in clinical trials 
may improve the clinician­participant relationship and 
satisfaction of participation, it may blur the line between 
clinical care and research. As researchers, it is important 
to understand what kind of research information partici­
pants may want and to consider the scope and nature of 
our responsibility to communicate results from the aims 
of a study, as well as incidental genetic findings that may 
affect a person’s health. These determinations are not 
straightforward and the environment is evolving rapidly. 
Investigators need to consider that there will be more 
and more opportunities for disclosure as the volume of 
genomic data in clinical trials research grows, our under­
standing of genetic contribution to health and illness 
expands, and practice norms surrounding giving genetic 
results to individual participants in research evolve. 
Investigators will also need to think carefully about when 
and how to present the possibility of discovering clinically 
relevant genomic findings that may not be the primary 
focus of the trial to study participants.
The issues of whether and how to return incidental 
genetic findings should be considered when determining 
which results from a trial will be reported. Once decided, 
plans related to sharing individual results from the aim(s) 
of the trial, as well as incidental findings, should be 
discussed explicitly in the consent form. IRBs and other 
study­specific governing bodies should be consulted 
when deciding if, when, and how to return incidental 
genetic findings, as they share responsibility with investi­
gators for study policies and procedures, and participant 
safety. The GARNET experience and consensus approach 
to incidental findings may be of help in informing such 
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